INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Cell & Gene Therapies in CNS Disorders Report 2025 - Zolgensma & Elevidys Lead Booming Cell & Gene Therapies in CNS Disorders [Yahoo! Finance]
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Morgan Stanley from $196.00 to $182.00. They now have an "overweight" rating on the stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $115.00 price target on the stock.